Skip to content
Cultural Foundation
Author:
Nanobiotix S.A.
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation
March 25, 2026
Voting Rights and Shares Capital of the Company
March 12, 2026
←
Previous Page
1
2